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Outcome measures are dependent on the type of therapy
phase:
In the treatment of depressive illness, the acute or short
phase of 6–8 weeks is focused on response and remission
in terms of symptom reduction. The continuation or
medium phase of the next 6–8 months of treatment
focuses on social functioning and subjective quality of
life.
In the acute treatment, the Hamilton Depression Scale
(HAM-D17) is the internationally most frequently used
scale, although the total score of all 17 items rarely has
been found to be a valid measure of severity of depressive
illness. the six-item Hamilton subscale (HAM-D6), on the
other hand, has consistently been shown to be a valid
scale to measure response or remission in controlled clin-
ical trials of antidepressants. Both the HAM-D6 and the
analogous six-item Montgomery-Asberg Depression Scale
(MADRS6) have been able to demonstrate dose-response
relationship with different antidepressants, in contrast to
HAM-D17.
In the continuation therapy, national norm scores on self-
rating scales measuring social functioning (e.g. SF-36) or
positive psychological well-being questionnaires (e.g.
WHO-5) are the goal of treatment. It has been demon-
strated that after only 12 weeks of therapy, social func-
tioning is restored in patients with major depression
treated with SSRIs, i.e. they obtain scores on the SF-36
subscale of social well-being within the range of the gen-
eral population scores.
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